Technical Analysis for ACTU - Actuate Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Calm After Storm | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -3.69% | |
| Outside Day | Range Expansion | -3.69% | |
| Wide Bands | Range Expansion | -3.69% | |
| Down 3 Days in a Row | Weakness | -3.69% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 13 hours ago |
| 50 DMA Support | about 13 hours ago |
| 2x Volume Pace | about 13 hours ago |
| 10 DMA Resistance | about 16 hours ago |
| 1.5x Volume Pace | about 16 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: Unknown
Actuate Therapeutics, Inc. Description
Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases. It is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis and neurodegeneration. The company aims to discover, develop, and commercialize new agents that target GSK-3?. Actuate Therapeutics is currently advancing its lead molecule, 9-ING-41, toward the clinic in 2017. Ongoing research has demonstrated significant anti-tumor activity in many in vivo models of difficult-to-treat cancers, including cancers of the brain, pancreas, lung, and breast. We are unaware of any published research demonstrating the kind of efficacy in treatment-resistant glioblastoma that we have been able to achieve with 9-ING-41. Importantly, the toxicity and pharmacokinetic profiles of the drug candidate are quite attractive.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Treatment Of Cancer Oncology Inflammatory Diseases Neurodegenerative Diseases Glioblastoma Fibrosis Aging Associated Diseases Neurodegenerative Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.162 |
| 52 Week Low | 5.52 |
| Average Volume | 43,161 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 7.70 |
| 20-Day Moving Average | 7.83 |
| 10-Day Moving Average | 8.22 |
| Average True Range | 0.75 |
| RSI (14) | 49.49 |
| ADX | 22.58 |
| +DI | 21.29 |
| -DI | 25.18 |
| Chandelier Exit (Long, 3 ATRs) | 7.63 |
| Chandelier Exit (Short, 3 ATRs) | 8.60 |
| Upper Bollinger Bands | 9.17 |
| Lower Bollinger Band | 6.50 |
| Percent B (%b) | 0.5 |
| BandWidth | 34.12 |
| MACD Line | 0.24 |
| MACD Signal Line | 0.19 |
| MACD Histogram | 0.0513 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.51 | ||||
| Resistance 3 (R3) | 9.51 | 8.96 | 9.23 | ||
| Resistance 2 (R2) | 8.96 | 8.53 | 8.96 | 9.14 | |
| Resistance 1 (R1) | 8.39 | 8.26 | 8.12 | 8.39 | 9.04 |
| Pivot Point | 7.84 | 7.84 | 7.70 | 7.84 | 7.84 |
| Support 1 (S1) | 7.27 | 7.41 | 7.00 | 7.27 | 6.62 |
| Support 2 (S2) | 6.72 | 7.14 | 6.72 | 6.52 | |
| Support 3 (S3) | 6.15 | 6.72 | 6.43 | ||
| Support 4 (S4) | 6.15 |
